European Psychiatry - Volume 41

S874

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S847–S910

EV1428

New designer benzodiazepines use in

Barcelona

S. Pérez González

∗

, M. De Dios Felis , E. Monteagudo Gimeno ,

D. Sanagustín Bosqued , A. Trabsa Biskri , M. Grifell Guàrdia ,

L. Galindo Guarín , P. Quintana Mathe , M. Torrens Melich

Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar,

Psychiatry, Barcelona, Spain

∗

Corresponding author.

Introduction

New designer benzodiazepines such as

phenazepam, etizolam, diclazepam, clonazolam and flubro-

mazolam have appeared in the recreational drug market due to

that they provide an attractive alternative to prescription-only

benzodiazepines as they are readily available over the Internet.

Objective

To describe the presence of new designer benzodi-

azepines in samples delivered to energy control since 2010 to 2016

in Barcelona.

Methods

From 2010 to 2016, 24,551 samples were delivered

to energy control. Among this samples 43 (0.175%) were anal-

ysed as benzodiazepines. They were analyzed by energy control,

a Spanish harm reduction NGO that offers the possibility of ana-

lyzing the substances that users report. Analysis was done by gas

chromatography-mass spectrometry.

Results

From the 43 samples analyzed as benzodiazepines, 1

(2.32%) was delivered in 2010, none in 2011, 2 (4.65%) in 2012,

2 (4.65%) in 2013, 1 (2.32%) in 2014, 15 (34.88%) in 2015 and 21

(48.83%) in 2016.

Discussion

The data shows that new designer benzodiazepines

use is increasing in Barcelona, especially in the last two years. Abuse

an addiction to these drugs may be a new public health problem in

Barcelona. Unknown side effects may appear due to lack of infor-

mation about pharmacokinetic profile of these drugs.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2017.01.1758

EV1429

Cognitive status and addiction denial

in the early stages of alcohol addiction

P. Ponizovskiy

∗

, A. Gofman

Moscow Research Institute of Psychiatry, Department of mental

disorders complicated by substance abuse, Moscow, Russia

∗

Corresponding author.

Introduction

Denial is a common feature of alcohol addiction that

is apparent in the early and late stages of the disease. Defensive psy-

chological mechanisms and cognitive failure have been reported

as reasons for addiction denial. Effective therapeutic approaches

should consider the reasons for anosognosic denial.

Aims and objectives

The study investigates the correlations

between the degree of denial of alcohol addiction and cognitive

status of people in the early stages of alcohol dependence.

Method

Subjects were identified using clinical interview the

AUDIT questionnaire investigating compulsive drinking, impaired

control of drinking, alcohol tolerance, and symptoms of with-

drawal.

Results

Forty-nine alcoholic patients at early stage of alcohol

dependence were identified. At assessment, all had been abstinent

for at least 7 days. They reported compulsive drinking, impaired

control over it, increased alcohol tolerance, but no withdrawal

symptoms followed by relief drinking. The level of denial was

defined by summing up the quantitative ratings of awareness of

alcohol addiction and its harmful effects. Three groups emerged

of non/mild, moderate, and severe levels of addiction denial. Neu-

ropsychological evaluation of verbal memory, logical memory,

visual-motor coordination, and motor and mental speed was con-

ducted.

Conclusion

The identified cognitive deficiencies in the 3 groups

were mild. Correlation between the poorer test performance and

higher levels of denial was not significant. In the early stages of alco-

hol addiction, the anosognosic denial appears to be an unconscious

ego defense mechanism leading to rejection of all the addiction-